Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing.
Lenz L, Clegg W, Iliev D, Kasten CR, Korman H, Morgan TM, Hafron J, DeHaan A, Olsson C, Tutrone RF Jr, Richardson T, Cline K, Yonover PM, Jasper J, Cohen T, Finch R, Slavin TP Jr, Gutin A.
Lenz L, et al. Among authors: cline k.
Prostate Cancer Prostatic Dis. 2024 Sep 5. doi: 10.1038/s41391-024-00888-y. Online ahead of print.
Prostate Cancer Prostatic Dis. 2024.
PMID: 39237680